Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 12/20 | 0.64 |
| ▸ | PGR | P06401 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292518 | 0.86 | NR3C1 (0.62) | NR3C1NR3C2PGR | |
| SCHEMBL4161358 | 0.84 | NR3C1 (0.70) | NR3C1NR3C2PGR | |
| SCHEMBL4941659 | 0.82 | NR3C1 (0.73) | NR3C1NR3C2PGR | |
| SCHEMBL292338 | 0.82 | NR3C1 (0.62) | NR3C1NR3C2PGR | |
| SCHEMBL4479134 | 0.80 | NR3C1 (0.70) | NR3C1NR3C2PGR | |
| SCHEMBL452414 | 0.79 | NR3C1 (0.85) | NR3C1NR3C2PGR | |
| SCHEMBL291954 | 0.79 | NR3C1 (0.85) | NR3C1NR3C2PGR | |
| SCHEMBL291643 | 0.79 | NR3C1 (0.79) | NR3C1NR3C2PGR | |
| SCHEMBL292098 | 0.79 | NR3C1 (0.62) | NR3C1NR3C2PGR | |
| SCHEMBL4466748 | 0.78 | NR3C1 (1.00) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | claimed |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | claimed |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| EP-2203160-A1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | Bausch & Lomb Incorporated (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| EP-2061444-A2 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | Bausch & Lomb Incorporated (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2056799-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | Bausch & Lomb Incorporated (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2051710-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051736-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009042377-A1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | BAUSCH & LOMB INCORPORATED (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008033655-A2 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH & LOMB INCORPORATED (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | BAUSCH & LOMB INCORPORATED | 2008-03-13 | — | — | US | disclosed |
| WO-2008027796-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | BAUSCH HEALTH COMPANIES INC. (CA) | 2008-02-07 | — | — | US | disclosed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | NR3C1, GNRHR, GSR | NR3C1 1/4885NR3C2 9/4885PGR 39/4885 |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 71/4885 |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885NR3C2 3/4885PGR 64/4885 |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | NR3C1 3/4885NR3C2 18/4885PGR 220/4885 |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885NR3C2 87/4885PGR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.